Cariprazine significantly improved symptoms in schizophrenia patients with negative symptoms and insufficient response to previous therapy, reducing the SAND total score by a mean of 7.3 points.
Observational (n=116)
Open-label
Yes
Does cariprazine improve negative symptoms in adult schizophrenia patients with insufficient effectiveness of previous antipsychotic therapy?
In a real-world observational setting, cariprazine significantly improved negative symptoms and overall illness severity in schizophrenia patients with insufficient response to prior antipsychotic therapy.
p-value: p=<0.001
The aim of the study was to examine the effectiveness and safety of cariprazine in routine psychiatric settings on schizophrenia patients with negative symptoms who have been treated with antipsychotics previously but without sufficient success. This was an open-label, flexible-dose, 16-week, observational study in Latvia. The primary outcome measure was an array of anamnesis-based clinical questions on schizophrenia symptoms rated on a seven-point scale. Other outcome measurements were the clinical global impression improvement (CGI-I) and severity (CGI-S) scales. Safety parameters included spontaneous reports of adverse events and specific assessments of extrapyramidal side-effects. A mixed model for repeated measures was fit to the data to evaluate the mean change from baseline for all visits. A total of 116 patients enrolled in the study (completion: 83%). Change from baseline to termination in symptom control was statistically significant (-7.3; P < 0.001), with the most improvement in negative symptoms (-6.3; P < 0.001). Over 70% of patients improved minimally or much based on the CGI-I scores at the final visit, and the CGI-S scores indicated an overall improvement in severity from moderately to mildly ill. 40% of patients experienced treatment-emergent adverse events. Over 70% of doctors were satisfied with the effectiveness and tolerability of cariprazine. Cariprazine significantly improved negative symptoms in schizophrenia patients.
Rancāns et al. (Fri,) conducted a observational in Schizophrenia with negative symptoms (n=116). Cariprazine was evaluated on Mean change from baseline to final visit in short assessment of negative domains (SAND) total score (95% CI -8.3 to -6.2, p=<0.001). Cariprazine significantly improved symptoms in schizophrenia patients with negative symptoms and insufficient response to previous therapy, reducing the SAND total score by a mean of 7.3 points.